bluebird bio (BLUE) Price Target Reduced to $149 at BofA/Merrill Lynch
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
bluebird bio to present LentiGlobin® BB305 Clinical Data and bb2121 Preclinical Data at Annual Meeting of the American Society of Hematology
November 5, 2015 8:00 AM ESTÂ Â Â Â Six abstracts accepted for presentation
Interim data on LentiGlobin in beta-thalassemia show six of six evaluable non-0/0 patients are transfusion-independent as of July 31st data cut-off; 0/0 patients have achieved varying degrees of transfusion reduction as of data cut-off
    Median production of corrected HbAT87Q globin: 5.2 g/dL among patients of all genotypes followed for at least six months in HGB-204 study, as of July 31st data cut-off
    Patient with sickle cell disease from HGB-205 study producing 51.5% anti-sickling... More
